TrialThe journal of prevention of Alzheimer's disease2025

Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease.

Erika N Cline et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.